Healthcare Providers and Services

Company Overview of Memorial Sloan Kettering Cancer Center

Company Overview

Memorial Sloan Kettering Cancer Center is a cancer care hospital that engages in cancer prevention, treatment, research, and education. It offers a range of programs to help patients and families throughout various phases of treatment, including genetic counseling, rehabilitation, integrative medicine, counseling, pain and palliative care, cancer screening, and assistance in navigating life after treatment. The company provides childhood cancer treatments, including blood and marrow transplantation, pediatric surgery, and subspecialty services; and treatments for adolescents and young adults with various types of cancers. Its research areas include cancer biology and genetics, cell biology, ...

Memorial Sloan Kettering Cancer Center is a cancer care hospital that engages in cancer prevention, treatment, research, and education. It offers a range of programs to help patients and families throughout various phases of treatment, including genetic counseling, rehabilitation, integrative medicine, counseling, pain and palliative care, cancer screening, and assistance in navigating life after treatment. The company provides childhood cancer treatments, including blood and marrow transplantation, pediatric surgery, and subspecialty services; and treatments for adolescents and young adults with various types of cancers. Its research areas include cancer biology and genetics, cell biology, computational biology, developmental biology, immunology, molecular biology, molecular pharmacology and chemistry, structural biology, epidemiology and biostatistics, human oncology and pathogenesis program, integrative medicine, medical physics, memorial hospital research, and psychiatry and behavioral sciences, as well as survivorship, outcomes, and risk programs. Memorial Sloan Kettering Cancer Center was formerly known as Memorial Hospital for the Treatment of Cancer and Allied Diseases and changed its name to Memorial Sloan Kettering Cancer Center in 1960. The company was founded in 1884 and is based in New York, New York with outpatient facilities in New York and Brooklyn, New York. It has suburban outpatient treatment centers in Basking Ridge and Middletown, New Jersey; and Commack, Rockville Centre, Hauppauge, Sleepy Hollow, and West Harrison, New York. The company has research facilities in New York, New York. It also has facilities in Fairfield County.

Memorial Sloan Kettering Cancer Center Key Developments

Enumeral Biomedical Holdings, Inc. announced that the company signed an agreement with Memorial Sloan Kettering Cancer Center as part of Enumeral’s Phase II Small Business Innovation Research contract with the National Cancer Institute. Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center. Dr. Wolchok played a critical role in the clinical development of ipilimumab and nivolumab, immunotherapies which represent a transformational advancement in the treatment of cancer. Enumeral’s Phase II program is focused on applying its human-driven immune profiling platform to small volume clinical specimens such as core biopsy or fine needle aspirates, which often contain limited numbers of cells and can be challenging to analyze with conventional technologies. Enumeral’s human-driven immune profiling platform has the ability to determine cellular function in an unbiased fashion, allowing analysis of rare immune cells associated with disease or drug response in even the smallest clinical samples. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response, which may ultimately guide development of more precisely targeted immunotherapies. Enumeral’s collaboration with MSK is supported by a Phase II SBIR contract from the NCI for $999,967 over two years. The NCI is funding the entirety of the program, which complements Enumeral’s other internal research and development efforts. Enumeral demonstrated proof of concept in this area under a Phase I contract in 2012 and 2013.

IBM announced a collaboration with Memorial Sloan Kettering to research the application of cognitive computing to analyze dermatological images of skin lesions with the goal of assisting clinicians in the identification of various cancerous disease states. The technology, which learns by identifying specific patterns in medical images, has the potential to increase the number of cases detected and help clinicians make earlier diagnoses. The automated analysis of skin imaging is one area of research that is currently being investigated by IBM Research, in conjunction with a larger international effort being led by Memorial Sloan Kettering.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.